Publications

Back to Publications

Find coverage of the latest original articles on Lupus, focusing on those with data on therapeutic interventions and those that have clinical impact.

This activity is supported by an educational grant from AstraZeneca.

Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two Phase 3 trials

Ann Rheum Dis 2024 DOI 10.1136/ard-2023-225445 Epub ahead of print https://pubmed.ncbi.nlm.nih.gov/38569851/

This longitudinal transcriptomic and proteomic analysis by Baker, et al. analysed 18 017 genes and 184 plasma proteins in patients enrolled in TULIP-1 or TULIP-2 to investigate immunomodulatory mechanisms of anifrolumab in SLE. Several intracellular signalling pathways downstream of IFN-α/-β29 were suppressed, including via JAK/STAT, phosphoinositide 3-kinases and NF-kB, and via MAPK pathways.

Keywords:


LinkedIn